Tolmar, Inc., a specialty pharmaceutical company, has officially opened its new Northern Illinois Laboratory at the Innovation and Research Park (IRP) of Rosalind Franklin University (RFU) in North Chicago, Illinois. This facility aims to enhance Tolmar’s capacity for developing and commercializing pharmaceutical products, while also contributing to the university’s environment of innovation.
Founded in 2007, Tolmar is recognized globally for its expertise in long-acting injectable drug delivery. The company specializes in developing and manufacturing injectables in areas such as urology, oncology, and endocrinology. Notably, one of its leading products is utilized in the treatment of advanced prostate cancer and is distributed in 89 countries.
The establishment of the new laboratory at RFU will complement Tolmar’s existing operation in Colorado, where a skilled team of researchers, engineers, and operational staff is already in place. The Illinois facility not only bolsters Tolmar’s research capabilities but also solidifies its regional presence, which includes executive offices and sales and marketing personnel in Buffalo Grove.
Dr. Dave Loffredo, vice president of innovation at Tolmar, expressed enthusiasm about the expansion. He stated, “After an exhaustive search, we found a great home at Rosalind Franklin’s IRP. Tolmar scientists are eager to be a part of this dynamic research environment and hope to grow our presence at IRP.”
The new facility is strategically located within RFU’s state-of-the-art, 100,000-square-foot IRP, which houses six research centers, including the Center for Cancer Cell Biology, Immunology, and Infection. This environment is designed to foster collaboration and innovation among various scientific disciplines.
Dr. Stace Porter, senior vice president of development operations for Tolmar, highlighted the advantages of the new location, stating, “At Rosalind Franklin University’s Innovation and Research Park, Tolmar gains world-class research space and the chance to collaborate with leading scientists and advanced research cores. Surrounded by Lake County’s vibrant network of global life science companies, we’re excited to grow and innovate here.”
Dr. Joseph DiMario, RFU’s executive vice president for research, welcomed Tolmar to the university’s ecosystem. He noted, “We look forward to collaborations that can help accelerate new product development. The IRP provides an environment that fosters the kind of intellectual biomedical ‘collisions’ that drive meaningful innovation.”
Tolmar is a fully integrated specialty pharmaceutical company focusing on the development, manufacturing, and commercialization of pharmaceuticals across multiple therapeutic areas. With its executive offices and commercial headquarters in Buffalo Grove, Illinois, Tolmar continues to expand its impact within the pharmaceutical industry.
Rosalind Franklin University, named after the pioneering scientist whose work was critical to understanding the structure of DNA, is recognized for its contributions to various research areas, including neuroscience, diabetes, and obesity. The university encompasses several colleges and schools, promoting a spirit of inquiry and excellence.
For further information about Tolmar, visit [www.tolmar.com](http://www.tolmar.com). To learn more about Rosalind Franklin University, go to [rosalindfranklin.edu](http://rosalindfranklin.edu).
